Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive Galantamine for Cognitive Impairments in Schizophrenia
NCT00176423Phase 4Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- May 2002
- Primary completion
- Dec 2006
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in schizophrenia and schizoaffective disorder comparing Galantamine Arm with Placebo Arm (2 arms). Primary endpoint: Overall Cognitive Improvement Z-score at 12 weeks. Started May 2002; status: completed.
02
Drugs
galantamine
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00176423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00176423.